Search results
Author(s):
Linda Joosten
Added:
7 months ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial.
FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists …
View more
Author(s):
Minh That Ton
,
Tri Huynh Quang Ho
,
Viet Lan Nguyen
,
et al
Added:
3 months ago
Author(s):
Tri Huynh Quang Ho
,
Minh That Ton
,
Viet Lan Nguyen
,
et al
Added:
3 months ago
Author(s):
Mandeep Mehra
,
Christian Inchaustegui
Added:
4 months ago
AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES…
View more
Author(s):
Harriette Van Spall
,
Mandeep Mehra
Added:
4 months ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were…
View more
Author(s):
Daniel TT Chong
,
Felicita Andreotti
,
Peter Verhamme
,
et al
Added:
2 years ago
Author(s):
Julia Sikorska
,
James Uprichard
Added:
3 years ago
For more than 50 years, oral vitamin K antagonists (VKAs) were the choice of anticoagulant for the long-term treatment and prevention of arterial and venous thromboembolic events (VTE). VKA treatment is safe and effective, if a high time in therapeutic range is achieved. However, achieving a stable, therapeutic international normalised ratio can prove challenging in the context of drug and food…
View more
Author(s):
Dipti Itchhaporia
Added:
4 months ago
AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.Trials discussed in detail include:SELECT: Semaglutide and Cardiovascular Outcomes in Obesity…
View more
Author(s):
S van Vugt
,
G Aarts
,
E Lamfers
,
et al
Added:
3 years ago
Objectives: Although polypharmacy is an accepted proxy for multi-morbidity, there has been limited attention for risk stratification among polypharmacy patients, especially in the elderly. We used the number of drug classes prescribed to determine the extent of co-morbidity and the risk of adverse outcome.
Methods: Prospective study among elderly patients (≥75 years) with polypharmacy (≥5 drugs)…
View more
Author(s):
Anna E Platek
,
Anna Hrynkiewicz-Szymanska
,
Karolina Semczuk
,
et al
Added:
3 years ago
Topic: 4. Arrhythmias
Introduction and Objectives
Atrial fibrillation (AF) patients can be managed with rate control and rhythm control strategies. Both seem to be equally safe and effective, and the decision should be made depending on patients and doctors’ preferences.1 The aim of the study was to compare patients with persistent AF in whom rhythm control strategy is chosen to those with…
View more